SCHEMBL25895403

SCHEMBL25895403

CC(=O)N1CC1C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13376686 0.81 PIK3CD (0.70)
SCHEMBL12244050 0.79 PIK3CD (0.44)
SCHEMBL18478122 0.73 SMN1; SMN2 (0.41)
SCHEMBL12428090 0.73 SMN1; SMN2 (0.41)
SCHEMBL13218350 0.73 FAP (0.42)
SCHEMBL8234453 0.73 FAP (0.42)
SCHEMBL13532952 0.73 FAP (0.42)
SCHEMBL5851955 0.72 MMP2 (0.33)
SCHEMBL7897243 0.72 CHRM2 (0.42)
SCHEMBL15423481 0.70 ATM (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed